Fig. 6From: Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracersMetabolism and pharmacokinetics of [18F]FEt-AMC13, [18F]FBu-AMC13, and [18F]FEt-AMC15 in the plasma of living rats. a Percentage of intact tracer in the total plasma radioactivity. b Concentration of intact tracer in the plasma (i.e., metabolite-corrected plasma input curves). Points represent group means, error bars show standard deviations. Horizontal axes show time after tracer injectionBack to article page